Pharma doesn’t just invent drugs—it also buys time.
In the race to recoup R&D costs, “extra time” can be worth billions. And nowhere is that more visible than in drug patent term extensions—an increasingly central strategy in how Big Pharma prote…

Cosentyx, a medication for multiple sclerosis, psoriasis, and psoriatic arthritis, works by blocking a protein called IL-17A…. https://www.Drugchatter.com/chat/20292/how-often-should-i-adjust-cosentyx/

A growing body of research suggests that natural cognitive boosters, such as those high in omega-3 fatty acids [1], may be… https://www.Drugchatter.com/chat/51408/can-lipitor-be-replaced-with-natural-cognitive-boosters/

Generic drugmakers don’t “wait their turn.” They litigate their way to it.
If you’ve ever wondered how some generics hit the market faster than expected, the answer often isn’t manufacturing capacity or regulatory luck—it’s patent strategy.
In a rece…

The real battleground in pharma isn’t patent expiry—it’s what you do before it.
As soon as a drug’s exclusivity window starts to narrow, the market stops rewarding “good enough” and starts rewarding speed, certainty, and defensibility. That’s why abu…

Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
Over the past few years, “old drugs” have been showing up in new places: in fresh clinical analyse…

A drug patent isn’t “worth” what the market says—it’s worth what you can defend.
In M&A, we love clean narratives: a pipeline, a label, a valuation model, a tidy headline number. But drug patents don’t trade like stocks. They trade like lawsuits….

Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …

Two clocks. One drug. And a lot of investors betting on the wrong one.
In pharma, timing isn’t just strategy—it’s destiny. Yet too many teams (and too many market narratives) treat “patent expiry” as the finish line. It isn’t.
A recent DrugPatentWatch …

Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/